Tetanus immunoglobulin: recommendations on treatment and prophylaxis

Recommendations on treatment of clinically suspected tetanus and prophylaxis of tetanus prone wounds.

This publication was withdrawn on

Please see Tetanus: guidance for health professionals for the latest guidelines.


[Withdrawn] Recommendations on the treatment and prophylaxis of tetanus

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email Please tell us what format you need. It will help us if you say what assistive technology you use.


In April 2018, updated interim guidance was issued in response to changes in available IV immunoglobulin products in the NHS. Based on testing carried out by NIBSC of 7 other IV immunoglobulin products to determine if they have similar levels of tetanus antibody, it was recommended that they may be used as alternatives to previously tested products for suspected clinical cases of tetanus.

PHE has recently become aware of a severe shortage of IM-TIG and Subgam available in the NHS, which are recommended for prophylaxis of tetanus-prone wounds. Furthermore, the alternative HNIG products that are approved for use by NHS England are also in limited supply. As a consequence, PHE has urgently reviewed the existing evidence and data to prioritise the use of TIG /HNIG for susceptible individuals who have sustained high risk injuries, and are at greatest risk. Guidance for classifying tetanus-prone injuries has also been revised to assist correct usage

Published 16 March 2013
Last updated 23 July 2018 + show all updates
  1. Added tetanus guidance revised due to the current shortage of tetanus immunoglobulin.
  2. Published interim guidance to address the current stock shortages of tetanus immunoglobulin.
  3. First published.